237 related articles for article (PubMed ID: 34678906)
1. The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation.
Shigemoto Y; Sakurada Y; Fukuda Y; Matsubara M; Parikh R; Kashiwagi K
Medicine (Baltimore); 2021 Oct; 100(42):e27580. PubMed ID: 34678906
[TBL] [Abstract][Full Text] [Related]
2. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
[TBL] [Abstract][Full Text] [Related]
3. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
4. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
[TBL] [Abstract][Full Text] [Related]
5. Sub-Tenon's capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation.
Hikichi T
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2529-2535. PubMed ID: 35235038
[TBL] [Abstract][Full Text] [Related]
6. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
7. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
8. Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration.
Mora P; Bellucci C; Radice LM; Manzotti F; Gandolfi S
Eur J Ophthalmol; 2024 Jan; 34(1):NP104-NP107. PubMed ID: 37424299
[TBL] [Abstract][Full Text] [Related]
9. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
[No Abstract] [Full Text] [Related]
10. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
[TBL] [Abstract][Full Text] [Related]
11. CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Angermann R; Huber AL; Nowosielski Y; Salcher S; Gasser T; Seifarth C; Kralinger MT; Zehetner C
Retina; 2022 Mar; 42(3):503-510. PubMed ID: 34731094
[TBL] [Abstract][Full Text] [Related]
12. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.
Yonekawa Y; Andreoli C; Miller JB; Loewenstein JI; Sobrin L; Eliott D; Vavvas DG; Miller JW; Kim IK
Am J Ophthalmol; 2013 Jul; 156(1):29-35.e2. PubMed ID: 23668679
[TBL] [Abstract][Full Text] [Related]
13. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
[TBL] [Abstract][Full Text] [Related]
14. Central retinal artery occlusion after intravitreal brolucizumab injection for treatment-naïve neovascular age-related macular degeneration; a case report.
Hong SH; Kim HD
BMC Ophthalmol; 2024 Apr; 24(1):200. PubMed ID: 38679743
[TBL] [Abstract][Full Text] [Related]
15. Preventive Inflammation Management with Steroids before Retreatment with Anti-VEGF after Severe Inflammation due to Brolucizumab.
Karmy BE; Castro DG; Ambresin A
Klin Monbl Augenheilkd; 2023 Apr; 240(4):556-562. PubMed ID: 37164395
[TBL] [Abstract][Full Text] [Related]
16. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
Khanani AM; Zarbin MA; Barakat MR; Albini TA; Kaiser PK; B G; Agashivala N; Yu JS; Wykoff CC; MacCumber MW
JAMA Ophthalmol; 2022 Jan; 140(1):20-28. PubMed ID: 34817566
[TBL] [Abstract][Full Text] [Related]
17. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER.
Singer M; Albini TA; Seres A; Baumal CR; Parikh S; Gale R; Kaiser PK; Lobach I; Feltgen N; Joshi MR; Ziemssen F; Bodaghi B
Ophthalmol Retina; 2022 Feb; 6(2):97-108. PubMed ID: 33971353
[TBL] [Abstract][Full Text] [Related]
19. Three Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic.
Hikichi T
Jpn J Ophthalmol; 2021 Mar; 65(2):208-214. PubMed ID: 33543351
[TBL] [Abstract][Full Text] [Related]
20. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration.
Messenger WB; Campbell JP; Faridi A; Shippey L; Bailey ST; Lauer AK; Flaxel CJ; Hwang TS
Br J Ophthalmol; 2014 Sep; 98(9):1205-7. PubMed ID: 24795334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]